Fosclevudine alafenamide

N/A

Report date: 2026/05/18 20:02:07
NME

Base Information

Drug NameFosclevudine alafenamide
Drug Alias NameATI-2173
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHBV DNA Polymerase inhibitors
TargetsHBV DNA Polymerase
Therapy Area/IndicationsHepatitis DHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[4
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAntios Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAntios Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHepatitis DHepatitis B, Chronic

Other Information

ATC CodeN/A
Related LinksN/A